An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF)

Leah Raj, 1 Bhavin Adhyaru 2

ABSTRACT
An estimated 5.1 million Americans have heart failure and this is expected to increase 25% by 2030.1 This results in nearly 1 million hospital admissions yearly due to heart failure.2 In 2014, 23% of heart failure-related deaths labelled heart failure as the underlying cause.3

Heart failure is a clinical syndrome that evolves from either functional or structural changes to the ventricles that lead to filling or ejection abnormalities.4 Disorders of the pericardium, myocardium, endocardium, heart valves or vessels can precede these changes; however, most commonly impaired left ventricular myocardial function is the culprit. Heart failure can be subdivided based on ejection fraction (EF). However, it is important to note that systolic and diastolic dysfunction can co-exist in both these groups. Heart failure with reduced ejection fraction (HFrEF) describes patients with a dilated left ventricle (LV) and EF <40%.3 In contrast, heart failure with preserved ejection fraction (HFpEF) indicates patients have EF >50% and a normal LV size. In the most recent update to the American College of Cardiology (ACC)/American Heart Association (AHA) heart failure guidelines, HFpEF is further subdivided into borderline (EF 41%-49%) and improved (EF >40%).4 However, there are few studies that evaluate pharmacotherapies in these populations. For the purpose of this review, we will focus on HFrEF.

Several mechanisms contribute to the development of heart failure. Neurohormonal activation, endothelial dysfunction, venous congestion and myocardial remodelling are just a few that can be named. In the early stages of heart failure, neurohormonal activation, such as the renin-angiotensin-aldosterone system (RAAS) enhances cardiac contractility, sodium and fluid retention and peripheral vasoconstriction in attempts to provide perfusion to organs.5 6 Despite initial benefits, over time these mechanisms lead to cardiac dysfunction and remodelling by fibroblast proliferation, oxidative stress and extracellular matrix deposition resulting in apoptosis and fibrosis.7 Venous congestion, either from progressive volume overload or rapid fluid shifts that induce the sympathetic system also lead to neurohormonal activation and its downstream effects.8 9 Vascular endothelium produces and metabolises nitric oxide. Along with cytokines and prostaglandins, nitric oxide alters myocardial function, haemodynamics and coronary and renal circulation.10

Some of the strongest predictors of decompensated heart failure include the presence of orthopnoea, paroxysmal nocturnal dyspnoea (PND), presence of an S3, evidence of jugular venous distension (JVD) or hepatojugular reflux, chest X-ray suggestive of oedema, and B-type natriuretic peptide (BNP) >250 pg/mL. Table 1 describes the sensitivity and specificity of many findings seen in decompensated heart failure.

The Framingham clinical criteria uses symptoms such as orthopnoea, paroxysmal nocturnal and elevated jugular venous pressure by requiring at least two major or one major and two minor criteria to diagnose heart failure (table 2). Apart from history and clinical signs and symptoms, imaging such as ECG, chest X-ray and transthoracic echocardiography can aid in diagnosis of heart failure.

Laboratory data are a vital component to diagnose heart failure. For example, elevated blood levels of BNP or N-terminal pro-B-type natriuretic peptide (NT-proBNP) are commonly elevated in heart failure. When the ventricular myocytes are under stress, they secrete prohormone pre-proBNP, which is cleaved into BNP and NT-proBNP. Secretion of these peptides induces vasodilation, diuresis and inhibits renin and aldosterone production.12 Decompensated heart failure is just one of many cardiac, as well as, non-cardiac disorders where elevated levels have been detected, such as sepsis, infiltrative diseases, cirrhosis, pulmonary embolism or renal failure.12

Natriuretic peptides have good prognostic implications. Elevated BNP has been associated with increased mortality and cardiovascular events in all patients with heart failure.12 13 In fact, in hospital mortality is higher in patients admitted for decompensated heart failure with a BNP >1730 pg/mL compared with those with BNP <430 pg/mL.14
Finally, BNP has also been evaluated in attempts to guide therapy based on its value, but results have been controversial. In one systematic review, patients with heart failure were treated based on BNP or clinical-guided therapy. In the cohort where treatment was based on BNP, it showed decreased hospitalisation due to heart failure, decreased cardiovascular disease and decreased all-cause mortality in patients aged <75 years.\(^{15}\) Currently, the ongoing PRIMA II trial is the first randomised clinical trial to investigate the impact of NT-proBNP-guided therapy during admission for acute heart failure on clinical outcomes as heart failure readmission and mortality rates. Interestingly, obesity can cause the BNP to be falsely low. In patients with a body mass index (BMI) >40, the BNP cut-off should be <100 pg/mL to rule out heart failure compared with 100 in a general population.\(^{16}\)

Heart failure can be classified according to either symptoms or evolution of the disease. The New York Heart Association (NYHA) functional classification assigns patients to one of four classes based on the effort needed to elicit clinical symptoms (table 3).

In comparison, the ACC/AHA heart failure stages emphasise the progressive development of heart failure and recognise risk factors and predisposition to the disease (table 4). Unlike the NYHA classification that can change depending on patient’s symptoms, the ACC/AHA classification is fixed and cannot be reversed.

Currently, the recommendations for treatment of stages A and B focuses on risk factor modification and treatment of atherothrombotic cardiovascular disease (ASCVD). The focus of this review will be on patients with chronic HFrEF who fall in stage C of disease.

**LIFESTYLE MODIFICATIONS**

Recommendations for lifestyle modification are based on data from observational studies as there are limited randomised trials exploring its effects. However, most patients are instructed to abstain from smoking, alcohol consumption and obesity. Most recently, it has been shown that overweight and obesity are associated with increased risk of heart failure. Specifically, a BMI >23 is associated with an increased incidence.\(^{17}\) Salt restriction is most commonly recommended; however, the ACC/AHA guidelines from 2013 merely state, “sodium restriction is reasonable for patients with symptomatic heart failure to reduce congestive symptoms”.\(^{4}\) Similarly, fluid restriction of 1.5–2 L is regarded as reasonable for stage D patients.\(^{7}\) Given the rationale that fluid retention leads to increased weight, daily weight monitoring is suggested for this patient population to prevent rehospitalisation.

**Cardiac rehabilitation**

Exercise in patients with heart failure has been proven to be safe. In fact, cardiac rehabilitation has been proven to reduce mortality, rehospitalisations and clinical symptoms in patients with HFrEF and is recommended for all patients who are able to participate.\(^{18,19}\)

**PHARMACOLOGICAL THERAPY**

There are many drugs available to treat HFrEF that either improves mortality or morbidity. In the past 5 years, there are several new classes of drugs with promising benefit. Table 5 summarises the pharmacotherapy for treatment of heart failure with the evidence base for their use.

### Table 1 Signs and symptoms of heart failure classified by sensitivity and specificity\(^{10}\)

<table>
<thead>
<tr>
<th>Sign/symptom</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>LR (+)</th>
<th>LR (−)</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of myocardial infarction</td>
<td>60</td>
<td>86</td>
<td>4.4</td>
<td>0.45</td>
</tr>
<tr>
<td>PND</td>
<td>41</td>
<td>84</td>
<td>2.6</td>
<td>0.70</td>
</tr>
<tr>
<td>Orthopnoea</td>
<td>50</td>
<td>77</td>
<td>2.2</td>
<td>0.65</td>
</tr>
<tr>
<td>Oedema</td>
<td>51</td>
<td>76</td>
<td>2.1</td>
<td>0.64</td>
</tr>
<tr>
<td>Dyspnoea on exertion</td>
<td>84</td>
<td>34</td>
<td>1.3</td>
<td>0.48</td>
</tr>
<tr>
<td>S3</td>
<td>13</td>
<td>99</td>
<td>11</td>
<td>0.88</td>
</tr>
<tr>
<td>Hepatojugular reflex</td>
<td>24</td>
<td>96</td>
<td>6.4</td>
<td>0.79</td>
</tr>
<tr>
<td>JVD</td>
<td>39</td>
<td>92</td>
<td>5.1</td>
<td>0.66</td>
</tr>
<tr>
<td>Lower extremity oedema</td>
<td>50</td>
<td>78</td>
<td>2.8</td>
<td>0.51</td>
</tr>
<tr>
<td>Chest X-ray findings of pulmonary congestion</td>
<td>54</td>
<td>96</td>
<td>12</td>
<td>0.48</td>
</tr>
<tr>
<td>ECG findings of atrial fibrillation</td>
<td>26</td>
<td>93</td>
<td>3.8</td>
<td>0.79</td>
</tr>
<tr>
<td>BNP &gt;250 pg/mL</td>
<td>89</td>
<td>81</td>
<td>4.6</td>
<td>0.14</td>
</tr>
</tbody>
</table>

BNP, B-type natriuretic peptide; JVD, jugular venous distension; PND, paroxysmal nocturnal dyspnoea.

### Table 2 Modified Framingham clinical criteria\(^{11}\)

<table>
<thead>
<tr>
<th>Major criteria</th>
<th>Minor criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paroxysmal nocturnal dyspnoea</td>
<td>Bilateral leg oedema</td>
</tr>
<tr>
<td>Orthopnoea</td>
<td>Nocturnal cough</td>
</tr>
<tr>
<td>Elevated jugular venous pressure</td>
<td>Dyspnoea on ordinary exertion</td>
</tr>
<tr>
<td>Pulmonary rales</td>
<td>Hepatomegaly</td>
</tr>
<tr>
<td>S3</td>
<td>Pleural effusion</td>
</tr>
<tr>
<td>Cardiomegaly on chest X-ray</td>
<td>Tachycardia (heart rate ≥120 bpm)</td>
</tr>
<tr>
<td>Pulmonary oedema on chest X-ray</td>
<td>Weight loss ≥4.5 kg in 5 days</td>
</tr>
<tr>
<td>Weight loss ≥4.5 kg in 5 days after medical treatment for heart failure</td>
<td></td>
</tr>
</tbody>
</table>

### Table 3 New York Heart Association functional classification of heart failure\(^{4}\)

<table>
<thead>
<tr>
<th>Class</th>
<th>Symptoms of heart failure only at levels that would limit normal individuals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I</td>
<td></td>
</tr>
<tr>
<td>Class II</td>
<td></td>
</tr>
<tr>
<td>Class III</td>
<td></td>
</tr>
<tr>
<td>Class IV</td>
<td>Symptoms of heart failure at rest</td>
</tr>
</tbody>
</table>

### Table 4 American College of Cardiology/American Heart Association heart failure stage\(^{6}\)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage A</td>
<td>Patients who are at high risk for developing heart failure, but have no structural disorder of the heart</td>
</tr>
<tr>
<td>Stage B</td>
<td>Patients with structural disorders of the heart who have never had symptoms of heart failure</td>
</tr>
<tr>
<td>Stage C</td>
<td>Patients with past or current symptoms of heart failure associated with underlying structural heart disease</td>
</tr>
<tr>
<td>Stage D</td>
<td>Patients with end-stage disease who require specialised treatment strategies</td>
</tr>
</tbody>
</table>
Known therapies for mortality benefit
ACE inhibitor/angiotensin receptor blocker
One of the first randomised clinical trials proving ACE inhibitor (ACEI) has mortality benefits in systolic heart failure was the Cooperative North Scandinavian Enalapril Survival Study. It looked at the effects of enalapril in patients with NYHA class IV and showed a 40% relative risk reduction in mortality in patients treated with enalapril compared with the placebo group. There was also an improvement in NYHA classification, reduction of heart size and medication requirement. Since then, trials such as the Studies of Left Ventricular Dysfunction showed mortality benefits in patients with asymptomatic heart failure and reduced left ventricular ejection fraction (LVEF), broadening the population that would benefit from ACEI therapy. In an effort to inhibit RAAS at another step, valsartan, an angiotensin receptor blocker (ARB), was tested in the Valsartan Heart Failure Trial (Val-HeFT). Although, valsartan had no survival benefit, it was shown to reduce morbidity and improve clinical signs and symptoms in patients with heart failure NYHA class II–IV when added therapy that included ACEI, β-blockers, diuretics or digoxin. The Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity trial published after Val-HeFT showed that candesartan showed a similar benefit to enalapril. The Valsartan in Acute Myocardial Infarction trial looked at ACEI versus ARB versus combination therapy and showed that ARB was non-inferior to ACEI and the combination group saw more adverse events. Current ACC/AHA guidelines recommend the use of ACEI (or ARB if patient cannot tolerate ACEI) in all patients with HFrEF.

β-Blockers
β-Blockers have been the cornerstone of systolic heart failure therapy for decades. They have been shown to improve mortality and morbidity, decrease cardiac remodelling and reduce hospital admissions. However, only three β-blockers have been proven to have this effect. The first is sustained-release metoprolol succinate, a selective β1-blocker, which showed a mortality benefit, reduced hospitalisations, improved NYHA functional class and quality of life in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure trial. The second β-blocker, carvedilol, a non-selective β-blocker and α-blocker, had similar results in the Carvedilol Prospective Randomized Cumulative Survival Study Group and the Carvedilol Heart Failure Study. Finally, the Carvedilol Insufficiency Bisoprolol Study (CIBIS) and CIBIS II trial demonstrated that bisoprolol, a selective β1-blocker, reduced mortality and readmissions. Therefore, these three selected β-blockers are recommended for all patients with current or prior symptoms of HFrEF.

More recently, the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure looked at the effects of nebivolol in elderly patients with heart failure. It was shown the addition of nebivolol decreases all-cause mortality and cardiovascular hospital admissions in patients with heart failure with reduced ejection fraction (HFrEF).
patients aged >70 years and currently not on β-blocker. However, this therapy is currently not recommended by ACC/AHA.

Mineralocorticoid receptor antagonist
In addition to ACEI and ARBs, aldosterone antagonists also inhibit steps of RAAS. The heart produces aldosterone in proportion to the severity of heart failure and also contains mineralocorticoid receptors (MCR). When the locally produced aldosterone works on the MCRs, this leads to stimulation of ACEI and RAAS. Using evidence from the Randomized Aldactone Evaluation Study and Eplerenone in Mild Patients Hospitalized and Survival Study in Heart Failure trial, current guidelines recommend addition of MCR antagonists to ACEI and β-blocker in patients with NYHA class II–IV and LVEF <35% as well as those following acute myocardial infarction (MI) in patients with LVEF <40 who develop symptoms of heart failure or have history of diabetes mellitus. This medication should be avoided if patients have renal failure with creatinine >2.0 mg/dL in men and 2.5 mg/dL in women and/or potassium >5.0 mg/dL.

Hydralazine-isororbide dinitrate
Hydralazine is a smooth muscle relaxant that works on arteriolar dilation and cardiac afterload. Isororbide dinitrate is a nitrate and venodilator, which improves cardiac preload. The combination of these drugs has proven to reduce mortality in patients with heart failure given their combined effort to reduce intracardiac filling pressures, which can reduce cardiac remodelling. In addition, hydralazine-nitrate therapy can enhance bioavailability of nitric oxide. The Vasodilator Heart Failure and African-American Heart Failure trials showed improved mortality compared with current medical management in a subset of patients, specifically African-Americans. Because of this, current guidelines indicate this combination therapy is recommended to reduce morbidity and mortality for African-American patients with NYHA class III–IV receiving medical therapy with ACEI and β-blockers.

Digoxin
Digoxin has multiple actions in patients with heart failure including positive inotropy, reducing rapid ventricular rate, vasodilation, increasing baroreceptor sensitivity, reducing plasma neurohormones, increasing vagal tones and diuresis. By inhibiting Na-K-ATPase pump in myocardial cells, it leads to increased intracellular sodium and calcium concentrations, and eventually improved isolated myocyte contractions and left ventricular systolic function. Several trials, most notably the Digitalis Investigation Group trial, have examined the efficacy of digoxin, comparing it with placebo, vasodilators and oral inotropic agents. All studies proved that it improved clinical symptoms, quality of life and lowered treatment failure rates; however, it did not improve survival. A newer medication, similar to digoxin, istaroxime, is being studied for heart failure benefit and the advantages include increased safety, improved contractility and less pro-arrhythymogenic than digoxin.

Therapies targeting symptomatic relief
Diuretics
As stated, thousands of people are admitted every year for acute decompensated heart failure. In attempts to relieve their volume overload symptoms, they are treated with intravenous and oral diuretics. It has been shown that 90% of patients hospitalised with acute decompensated heart failure receive intravenous loop diuretics during the hospitalisation. Importantly, the Diuretic Optimization Strategies Evaluation trial proved that there were no significant differences is clinical symptoms comparing bolus and continuous infusions of intravenous furosemide. However, no study has proven any mortality of benefit when using diuretics and currently they are recommended solely for symptomatic relief. The available diuretics include furosemide, torsemide and bumetanide. The benefits of torsemide and bumetanide include increased oral bioavailability and metabolism by the liver (compared with kidneys with furosemide). Of note, there are also some studies that suggest torsemide may reduce recurrent hospitalisations for decompensated heart failure compared with furosemide.

Inotropes
Therapies such as left ventricular assist device (LVAD) or transplantation are mainstays of end-stage heart failure due to their ability to improve cardiac output. Inotropes also increase cardiac output, but do not exhibit the same long-term effect. Currently, milrinone and dobutamine are the only inotropes approved for use. They both increase intracellular level of cyclic AMP. Dobutamine is a sympathomimetic amine, which binds to β1, β2 and α1 adrenergic receptors. This leads to an inotropic effect, as well as a weak chronotropic effect. Specifically, α1 agonist activity leads to vasoconstriction balancing β2 agonist vasodilatory effects, resulting in unchanged blood pressure. In contrast, milrinone is a phosphodiesterase-3 inhibitor that increases cardiac contractility and reduces afterload by altering left ventricular filling pressures.

Prolonged use of both inotropes can lead to ‘inotrope dependence’ defined by withdrawal leads to symptomatic hypotension, recurrent congestive symptoms or worsening renal function. Because of this, randomised clinical trials examining inotrope versus placebo have been ethically challenging and most data rely on retrospective analysis. The Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness trial evaluated 6-month mortality in patients with heart failure receiving inotropes reached 19%. More so, analysing the Acute Decompensated Heart Failure National Registry showed 200% increase of in-hospital mortality in patients treated with inotropes compared with vasodilators.

Most recent ACC/AHA guidelines from 2012 recommend inotropic agents in patients with stage D refractory to medical and device therapy who are waiting for LVAD or transplantation as bridge to therapy or palliative agent in symptomatic patients. It is also indicated as short-term support in patients with severe systolic dysfunction hospitalised presenting with low blood pressure at risk for end-organ damage.

New therapies
Sacubitril/valsartan
In additional attempts to minimise the activation of RAAS and the natriuretic peptide system, sacubitril/valsartan was developed. It has two separate components. The first drug is valsartan, already known to block angiotensin type 1. The second is a neprilysin inhibitor (NEPI) prodrug, sacubitril. This is converted to an enzyme that inhibits NEP and breaks down atrial natriuretic peptide (ANP), BNP and C-type natriuretic peptide. In addition, it has the ability to decrease vasoconstriction, sodium retention and maladaptive remodelling.

This drug has the potential to inhibit two systems that lead to progression of heart failure. Some of the earlier trials evaluating NEPI compared with ACEI showed promise, but many had increased risk of angioedema. A study evaluating NEPI and
ACEI versus ACEI alone showed increased risk of angioedema in the NEPI/ACEI group. As a result, the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure evaluated an ARB/NEPI compared with ACEI. Inclusion criteria were NYHA class II-IV with EF ≤40%, plasma BNP ≥150 or BNP ≥100, if the patient was hospitalised for heart failure within the past 12 months. The primary end point was the composite of cardiovascular mortality or hospitalisation for heart failure. In this prospective, double-blind, randomised trial, patients were randomly assigned to the sacubitril/valsartan or enalapril. The study was stopped early given significant reductions in both primary end point and cardiovascular death. Sacubitril/valsartan reduced cardiovascular death or heart failure-related hospitalisation by 20% and all-cause mortality by 16%. Additionally, the risk of angioedema was no different between the groups. However, there was a higher risk of symptomatic hypotension in the valsartan/sacubitril group. Recently, the Food and Drug Administration (FDA) approved this new therapy for heart failure treatment in patients with NYHA class II-IV with the goal of reducing mortality.

Ivabradine
Elevated heart rate is thought to contribute to increased morbidity and mortality in patients with heart failure. In patients with coronary artery disease and LV dysfunction, a heart rate of 70 bpm or higher was associated with 34% increase of cardiovascular death and 53% increase in admission to the hospital for heart failure compared with those patients with a heart rate <70 bpm. Tachycardia has also been shown to be a predictor of systolic function and therefore heart failure. Ivabradine selectively inhibits If current in the sinoatrial node, which is partially responsible for pacemaker activity. By reducing sinoatrial node (SA) nodal discharge, this new drug is able to reduce the heart rate. Unlike β-blockers, which also reduce heart rate, it does not affect myocardial contractility or intracardiac conduction.

In the Systolic Heart Failure Treatment with the If inhibitor Ivabradine trial, ivabradine was examined in addition to guideline-based treatment on cardiovascular outcomes, symptoms and quality of life in patients with chronic heart failure and systolic dysfunction. In this double-blind, placebo-controlled clinical trial, participants had moderate-to-severe heart failure, LV systolic dysfunction, resting heart rate >70 bpm, recent hospitalisation for heart failure within the previous year and were on stable treatment including a β-blocker, if tolerated. Patients were randomly assigned to placebo or ivabradine. The primary end point was the composite of cardiovascular death or hospital admission for worsening heart failure. Study showed significant reduction in heart failure hospitalisations in the ivabradine arm compared with placebo (16% vs 21% with p<0.0001). It also showed a 18% relative risk reduction in the primary end point and reduction in deaths due to heart failure in the ivabradine arm compared with placebo (3% vs 5% with p<0.014). However, there were several problems with this trial including that not all patients were on β-blockers (89%) and only 56% of patients were receiving 50% or more of the targeted β-blocker dose.

In April 2015, ivabradine was FDA approved for patients with chronic stable heart failure, with EF <35% who are unable to tolerate β-blockers or are on maximally tolerated β-blockers with a resting heart rate >70 bpm.

Aikskiren
Val-HeFT study showed that there exists a relationship between plasma renin activity and subsequent major cardiovascular events in patients with systolic heart failure. Aikskiren is labelled as a direct renin inhibitor, but benefits include inhibiting all downstream effects of renin, including RAAS.

Aikskiren was investigated in the Aikskiren Trial on Acute Heart Failure Outcomes trial regarding reduction of rate of cardiovascular death or heart failure rehospitalisation among patients with heart failure. It was a double-blind, placebo-controlled study that randomised hospitalised patients with heart failure into aikskiren or placebo. Eligible patients included those with EF <40%, elevated natriuretic peptides and signs and symptoms of fluid overload. The primary end point was measured as cardiovascular death or heart failure rehospitalisation at 6 or 12 months. It was found that initiation of aikskiren in addition to standard therapy did not reduce cardiovascular death or heart failure rehospitalisation at 6 or 12 months after discharge. Interesstingly, a subgroup analysis showed that patients with diabetes and who received aikskiren had a higher risk of death compared with non-diabetics. The recently published Aikskiren Trial to Minimize Outcomes in Patients with Heart Failure trial evaluated the role of aikskiren monotherapy compared with enalapril and combination therapy. The primary outcome was death from cardiovascular disease or hospitalisations for heart failure. The patients included had an average age of 63, LVEF of 28% and about 30% of patients had diabetes mellitus. Over a follow-up period of 36.6 months, the authors did not show non-inferiority with aikskiren compared with enalapril and the combination group had more adverse events. Thus, the evidence is clear that the role for direct renin inhibition in heart failure is not clear for now.

Other pharmacotherapies
Calcium-channel blockers
There are two general categories of calcium-channel blockers (CCB) including the dihydropyridine (DHP) and non-dihydropyridine (non-DHP). The DHP CCB class includes amlo-dipine, felodipine and nifedipine and the non-DHP CCB class includes diltiazem and verapamil. Most of the trials evaluating the non-DHP and first-generation DHP CCB have shown worse outcomes in heart failure, hence they should be avoided in patients with decompensated heart failure or chronic HFrEF as they have negative inotrope effect and can worsen heart failure symptoms.

One randomised controlled trial (RCT), the Prospective Randomized Amlodipine Survival Evaluation trial, evaluated a second-generation non-DHP CCB, amlodipine. The outcome was combined risk of all-cause mortality and cardiovascular morbidity. The results showed a non-significant reduction (relative risk reduction 9%, p=0.31) in the primary outcome. As a result, current ACC recommendations state that CCB are not recommended as a routine treatment in patients with HFrEF and that non-DHP CCB should be avoided due to the negative inotrope effect.

Anticoagulation
Patients with HFrEF are at risk of having thromboembolic events given a hypokinetic LV and relative stasis of blood. However, the risk of a thromboembolic event is 1%–3% per year in this population. Several retrospective studies showed that the risk of embolic events was not lower in patients taking warfarin compared with placebo, but the risk of bleeding was much higher. The data on warfarin in reducing cardiovascular events and death in heart failure are mixed.

An RCT in 2009, the Warfarin and Antiplatelet therapy in Chronic Heart failure (WATCH) study compared aspirin, warfarin and clopidogrel for the primary outcome of all-cause mortality, non-fatal MI and non-fatal stroke. The results showed no
statistical difference in superiority of either warfarin or clopidogrel to aspirin in the primary outcome.61 There was a significant reduction in non-fatal stroke in using warfarin.

Another RCT directly comparing warfarin with aspirin is the The Warfarin vs Aspirin in Reduced Cardiac Ejection Fraction trial (WARCEF). This RCT included 2305 patients randomised to warfarin or aspirin (325 mg daily). The primary outcome was a composite of time to death, ischaemic stroke or intracerebral haemorrhage. The results showed a non-significant reduction in the composite outcome in the warfarin group, but a significant reduction in ischaemic stroke in the warfarin group similar to that seen in the WATCH study.62 However, there was also a higher risk of intracranial haemorrhage in the warfarin group.

A trial comparing clopidogrel with aspirin is currently ongoing. However, given the unclear evidence for aspirin or its dosing in the absence of coronary artery disease, it should likely not be used in heart failure. As a summary, the current guidelines do not recommend anticoagulation without known atrial fibrillation, a prior thromboembolic event or a cardioembolic source.

Iron supplementation and erythropoietin therapy

There has been much interest in the treatment of anaemia and its impact on heart failure. It has been associated with an increased risk in mortality in heart failure, decreased exercise capacity and impaired quality of life and increased risk for hospitalisation.63 There are two types of therapies that have been looked at: iron supplementation and erythropoietin-stimulating agents.

The Ferric Carboxymaltose Assessment in Patients with Iron Deficiency and Chronic Heart Failure With And Without Anemia trial evaluated the role of intravenous iron supplementation in heart failure. Interestingly in this trial, anaemia was not a requirement for inclusion and half the patients had a haemoglobin (Hb) >12 g/dL. The patients enrolled had depressed left ventricular systolic function and NYHA class II–III and a ferritin <100 µg/L or between 100 and 299 µg/L if the transferrin saturation was <20% (haemoglobin was between 9.5 and 13.5 g/dL). The study showed improvements in functional status with improved self-reported patient global assessment at 24 weeks.64 However, it is unclear whether this confirms a mortality benefit.

The Reduction of Events with Darbepoetin Alfa in Heart Failure trial evaluated treatment of anaemia using darbepoetin alfa in systolic heart failure. The study included patients with an average age of 72, with NYHA class II–IV symptoms, LVEF <40% and Hb 9.0–12.0 g/dL that were on guideline-directed therapy. The patients were randomised to darbepoetin alfa or matching placebo and the primary outcome was a composite death from any cause or first hospitalisation from worsening heart failure. The study did not show a statistically significant benefit with darbepoetin and there were more thrombotic and embolic events in the darbepoetin group.65 Currently, there are no recommendations by the ACC/AHA on the role of either iron or darbepoetin in the management of heart failure.

Statins

The data for use of statins in symptomatic heart failure are not robust because these patients are typically excluded from many of the RCTs. The theory for statin benefit in heart failure is thought to be related to the pleotropic effects of statins involving anti-inflammatory activity and improvements in endothelial function.

The Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA) was an RCT of 5011 older patients (≥60 years) with NYHA class II–IV (average EF 27%) randomised to placebo or rosuvastatin. The primary outcome in this trial was a composite of death from cardiovascular disease, non-fatal MI or stroke. The rosuvastatin group had a reduction in low-density lipoprotein-cholesterol to 76 mg/dL at 3 months.66 Although, the HR for the primary outcome was 0.95 with no statistical significance, there was a significant decrease in hospitalisation for cardiovascular causes in the statin group. One of the limitations of this study was the use of older patients with more severe heart failure and likely suffered from advanced cardiovascular disease.

The Effect of rosuvastatin in patients with chronic heart failure trial failure trial (GISSI-HF) study was an RCT examining a broader range of patients with NYHA class II–IV with variable EF and aetiology. The primary outcome was time to death and time to death or admission to hospital for cardiovascular reasons. The study found no statistical difference with rosuvastatin on death or hospitalisation for cardiovascular reasons.67 A study pooled together data from the CORONA and GISSI-HF trials showed a reduction in MI of 19% using rosuvastatin in patients with ischaemic heart failure.68 It is important to highlight that in the meta-analysis the absolute risk reduction was only 1.1% given the low number of MI. It is also important to consider the heterogeneity in pooling these patient populations given the very different population characteristics.

The ACC/AHA heart failure guidelines do not specifically address the role of statins in heart failure; however, the most recent updated ACC Consensus Committee does recommend statin in patients with ASCVD and NYHA class II–III heart failure due to ischaemic disease.

There may be some evidence to suggest the use of omega-3-polyunsaturated fatty acid (PUFA) as therapy for heart failure. In GISSI-HF trial, investigators found a small significant reduction in death from any cause of 9%.69 The ACC/AHA guideline suggests PUFA is reasonable to use adjunctive in patients with NYHA class II–IV.

FUTURE DIRECTIONS

Ularitide

Urodilatin is a human natriuretic peptide produced in the kidney by processing pro-ANP that aids in water and salt reabsorption.69–71 A synthetic form of urodilatin is ularitide, which has been shown to induce natriuresis, diuresis, vasodilation and inhibition of RAAS.72–74 Thus far, clinical trials prove
that it leads to vasodilation and lowers cardiac filling pressures. It is currently in phase III of the Trial of Ularitide’s Efficacy and Safety in Patients with Acute Heart Failure, which examines symptoms and cardiovascular mortality in patients with acute decompensated heart failure.74

CONCLUSION
Despite numerous advances in therapy, both pharmacological and implantable, heart failure continues to be a deadly disease accounting for up to one in nine deaths in the USA. Several therapies, including β-blockers, ACEI, aldosterone antagonists, hydralazine-isosorbide dinitrate combinations have been mainstay therapy for decades. However, newer therapies such as sacubitril/valsartan, ivabradine and aliskiren have been shown to improve mortality and hospital readmission rates. Future directions likely include more pharmacological therapies as well as gene therapy hoping to reduce fatalities and improve quality of life of these patients.

Current research questions

▶ Heart failure and renin-angiotensin-aldosterone system have been closely linked for decades. Thus far, we have pharmacotherapies that inhibit both ACEI and ARB. However, there are several steps in the pathway that have not been able to be blocked. Can future directions of research focus on these different gateways?
▶ Natriuretic peptides play a vital role in heart failure. Most importantly, elevated values have been found in volume-overloaded states. Reviews have attempted to guide therapy based on its value, but there has been no consensus on its utility. Will trials in the future be able to investigate natriuretic-guided therapy in attempts to minimise readmissions and hospital length of stay?
▶ There are some data on combination or poly-pills emerging to treat cardiovascular disease. Some research shows that these may improve adherence and improve mortality. Given several pharmacotherapies that improve mortality in heart failure, is the next step in heart failure management the development of a poly-pill?

Key references


Self assessment questions

Please answer True or False to the below statements.

1. What pharmacological therapy has been shown to reduce mortality in patients with New York Heart Association (NYHA) class III–IV heart failure with reduced ejection fraction (HFrEF)?
   A. Sacubitril/valsartan
   B. Aliskiren
   C. Furosemide
2. First-line therapy for HFrEF include all of the following except:
   A. ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB)
   B. β-Blocker
   C. Digoxin
3. Ivabradine is recommended for patients with chronic, symptomatic NYHA class II–III HFrEF who have all of the following except:
   A. Ejection fraction (EF) <35%
   B. Unable to tolerate β-blockers
   C. Currently on β-blocker with resting heart rate >90 bpm
4. Increased natriuretic peptides have been shown to be associated with
   A. Increased cardiovascular events
   B. Decreased mortality
   C. Increased readmission rates for heart failure
5. According to the American College of Cardiology/American Heart Association guidelines, which calcium-channel blocker (CCB) has been associated with harm and therefore is not recommended?
   A. Verapamil
   B. Amlodipine
   C. Nifedipine

Contributors LR and BA determined structure and content of the paper, LR wrote the paper, BA aided with editing and revising the paper.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES
Review


**Answers**

1. A. True. Based on Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure study
   B. False. Thus far, randomised controlled trials have had mixed results, including Aliskiren Trial on Acute Heart Failure Outcomes and Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure
   C. False. Has not been shown to reduce mortality. It is only given for symptom management

2. A. True. Based on current guidelines
   B. True. Based on current guidelines
   C. False. Proven to reduce clinical symptoms, but not currently first-line therapy

3. A. True
   B. True
   C. False

4. A. True
   B. False
   C. False

5. A. True. Non-dihydropyridine CCB which negative chronotropic effect
   B. False
   C. False